{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.0"}]}],"title":"SC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0"}]}],"title":"IV"}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"}],"units":"Participants"}],"description":"The Participant Choice Questionnaire offered participants SC or IV treatment administration choices for the Treatment Continuation Period of the study, and was administered on Day 106 after study intervention administration. As pre-specified by the sSAP, the percentage of participants who chose either SC or IV treatment for the Treatment Continuation Period in the study was reported out of all randomized participants who chose to receive treatment intervention in the Treatment Continuation Period.","groups":[{"description":"Randomized participants received three doses of pembrolizumab plus berahyaluronidase alfa SC and three doses of pembrolizumab IV during the Treatment Crossover Period and subsequently chose to receive treatment in the Treatment Continuation Period via the Participant Choice Questionnaire.","id":"OG000","title":"Participants Continuing Treatment in Continuation Period"}],"paramType":"NUMBER","populationDescription":"The analysis population included all randomized participants who chose to receive treatment intervention in the Treatment Continuation Period via the Participant Choice Questionnaire. Six participants included in the analysis chose to receive treatment in the Treatment Continuation Period but discontinued before receiving actual treatment.","reportingStatus":"POSTED","timeFrame":"Day 106","title":"Percentage of Participants Who Chose Pembrolizumab (+) Berahyaluronidase Alfa SC or Pembrolizumab IV for the Treatment Continuation Period on the Participant Choice Questionnaire","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}